- Patient profile
- M, age band 40–49, United States
- Outcome scale
- EDSS (lower is better)
Twelve-month EDSS follow-up for a US patient with relapsing-remitting MS who underwent an intravenous plus intrathecal Wharton's Jelly MSC protocol in Istanbul.
RRMS response to MSC therapy is heterogeneous. Disease-modifying therapy was continued; this case does not isolate the contribution of MSCs from background DMT effect, and is not a predictor of any other patient's outcome.
EDSS timeline
EDSS quantifies neurological disability in MS from 0 (normal exam) to 10 (death from MS). Changes of ≥0.5 at higher baselines and ≥1.0 at lower baselines are typically considered meaningful.
| Timepoint | EDSS | Δ vs baseline |
|---|---|---|
| Baseline | 4.5 | — |
| Day 90 | 4 | -0.5 |
| Day 180 | 3.5 | -1 |
| Day 365 | 3.5 | -1 |
Relapsing-remitting MS, 9 years since diagnosis. Stable on disease-modifying therapy with two relapses in the prior 24 months. Baseline EDSS 4.5 driven primarily by gait and lower-limb fatigue at >300 m walking distance.
Intravenous Wharton's Jelly MSCs across two sessions with one intrathecal administration under sterile fluoroscopic guidance, alongside continued neurology follow-up in the US. Total Istanbul program: 5 days.
EDSS captured at Days 90, 180 and 365 by the patient's home neurologist and shared with the program coordinator. Walking distance self-reported at >500 m without rest at Day 180 and maintained at Day 365. No relapses recorded in the 12-month observation window.
Transient post-lumbar-puncture headache for 36 hours, resolved with hydration and supine rest. No infections. No systemic adverse events.
